Get started
Author

Eleni Florou

Observed name: Helena Florou
ORCID: 0000-0002-1201-099X
Observed ORCID: 0000-0002-1201-099X
OpenAlex ID: A5088109292
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
2021 · Evdoxia Kyriazopoulou, Garyfallia Poulakou, et al. · Nature Medicine · 565
PDF
Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial
2025 · Evangelos J. Giamarellos-Bourboulis, Antigone Kotsaki, et al. · JAMA · 152
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
2021 · Evdoxia Kyriazopoulou, Garyfallia Poulakou, et al. · Nature Medicine · 34
PDF
Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host
2024 · Evdoxia Kyriazopoulou, Karolina Akinosoglou, et al. · International Journal of Antimicrobial Agents · 9
Long-term immune and epigenetic dysregulation following COVID-19
2025 · Chrysanthi Sidiropoulou, Garyphallia Poulakou, et al. · Clinical Immunology · 3
A human-specific long noncoding RNA regulator of antigen-presenting cell viability and antimicrobial defense
2026 · Alexander J. Westermann, Alexandra Schock, et al. · Proceedings of the National Academy of Sciences · 2
Works count: 6
Citation count: 765
H-index: 4
I10-index: 3
Year
Topic
Type